Metsera announced interim Phase 2 results for its obesity drug MET-097i demonstrating an average placebo-adjusted body weight reduction of approximately 14% at 28 weeks, paralleling Lilly’s Zepbound efficacy. The data also highlight a dosing regimen that potentially improves gastrointestinal tolerability, with lower rates of nausea and vomiting compared to existing GLP-1 therapies. Pfizer recently agreed to acquire Metsera for $4.9 billion, aiming to strengthen its position in the lucrative obesity drug market, anticipated to exceed $100 billion annually within a decade. These findings set the stage for further Phase 3 studies under Pfizer's stewardship.